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a b s t r a c t
Dual differentiation therapy with arsenic trioxide and tretinoin (all-trans-retinoic acid; ATRA) for the
management of low and intermediate risk acute promyelocytic leukemia has recently been recom-
mended by the National Comprehensive Cancer Network. Some less common toxicities of the
combination may have yet to be fully realized. Of ten patients we have treated thus far, ﬁve (50%) have
developed pseudotumor cerebri. In one patient, temporary discontinuation of ATRA and initiation of
acetazolamide controlled symptoms. In four patients, topiramate was substituted for acetazolamide to
relieve symptoms and allow ATRA dose re-escalation. We conclude that providers should monitor for
pseudotumor cerebri and consider topiramate if acetazolamide fails.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
1. Introduction
Acute promyelocytic leukemia (APL) is an aggressive myeloid
malignancy deﬁned by the presence of the PML-RARα fusion gene
produced by a translocation between chromosomes 15 and 17.
Through risk stratiﬁcation and incorporation of tretinoin (all-
trans-retinoic acid; ATRA) into treatment, patient outcomes have
drastically improved with complete response (CR) rates reaching
490% when combined with chemotherapy [1–3]. Most recently,
dual differentiation therapy with ATRA and arsenic trioxide (ATO)
(Table 1), has become a recommended ﬁrst-line regimen by the
National Comprehensive Cancer Network for the management of
patients with low/intermediate risk APL (white blood cell (WBC)
count o10109/L), or patients with high risk disease who are
unable to receive anthracycline-based chemotherapy [4]. ATO
binds to the PML end of the fusion protein resulting in apoptosis
of APL cells [5]. A randomized controlled trial by Lo-Coco et al. [6]
demonstrated complete remission rates of 100% with dual differ-
entiation therapy, proving non-inferiority of the ATO-ATRA com-
bination over ATRA plus chemotherapy in the management of low/
intermediate risk APL.
Pseudotumor cerebri (PTC), also known as idiopathic intracranial
hypertension, is a condition characterized by an increase in intracra-
nial pressure, without cerebrospinal ﬂuid (CSF) abnormalities or
radiological evidence of other intracranial pathology (hydrocephalus,
mass, structural or vascular lesion) [7]. PTC following ATRA adminis-
tration for APL has been well described [8–26]. However, reports of
PTC resulting speciﬁcally from dual differentiation therapy are cur-
rently lacking, and there is a paucity of evidence describing manage-
ment of this condition speciﬁcally in patients with APL, where
continuation of therapy is necessary for optimal clinical outcomes.
Although the exact mechanism of ATRA induced PTC is
currently unknown, a variety of medications are used in its manage-
ment including carbonic anhydrase inhibitors, diuretics, corticoster-
oids, and analgesics. Acetazolamide, a carbonic anhydrase inhibitor,
is the most commonly used agent in the management of non-drug
induced PTC and is thought to work through reduction of CSF
production. More recently, the anticonvulsant topiramate has been
viewed as an attractive treatment option for idiopathic PTC given
its activity as a carbonic anhydrase inhibitor (mostly at receptor
subtypes II and IV) and its efﬁcacy as a migrainolytic [27–29]. The
precise mechanism of both migrainolysis and anti-epileptic efﬁcacy
is unknown, however the drug is known to antagonize sodium
channels, augment the effect of gamma-aminobutyrate (GABA) at
receptor subtype A, and antagonize the AMPA/kainate subtypes of
the glutamate receptors [30].
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From November 2012, through January 2014, ten patients with
low or intermediate risk APL received upfront dual differentiation
therapy with the ATO–ATRA combination [4]. Out of these ten
patients, we describe ﬁve (50%) cases of PTC which occurred
following the initiation of dual differentiation therapy and their
clinical courses, with an emphasis on our experience with the
substitution of topiramate in place of acetazolamide in non-
responders.
2. Case 1
A 54 year old African American male was transferred to RPCI
where workup revealed a diagnosis of APL (Table 2) and dual
differentiation therapy was subsequently initiated (Table 1). That
same evening, he complained of severe headache that was out of
the ordinary for himwith no other symptoms. Of note, he was also
receiving concomitant diltiazem CD 180 mg daily, a medication
known to inhibit CYP3A4 [31]. A head CT scan was without any
abnormalities, and a lumbar puncture (LP) revealed an elevated
intracranial pressure (ICP) of 35 cm H20. ATRA was interrupted,
and acetazolamide was started at 250 mg orally twice daily. After
two days, his headache resolved and ATRA was restarted with an
80% dosage reduction. Headaches resumed upon ATRA reintroduc-
tion. However, therapy was continued, and acetazolamide was
increased to 500 mg orally twice daily.
Acetazolamide was unable to relieve the headaches and was
discontinued. Topiramate was initiated, with subsequent headache
relief noted at a dose of 100 mg orally twice daily. With this
therapy, ATRA was able to be re-titrated to a maximum of 40 mg
orally twice daily (80% of initial dose) over two weeks until PTC
recurred. Following therapeutic lumbar puncture, ATRA was
resumed at 30 mg orally twice daily. A topiramate dose of
150 mg orally twice daily was needed to control symptoms for
the remainder of induction. At no point during treatment was ATO
interrupted. Upon discharge, the patient was prescribed topira-
mate 100 mg orally twice daily to begin the day prior to starting
ATRA consolidation. He completed consolidation as planned. Four
months following therapy completion, he remains in CR.
3. Case 2
A 24 year old Caucasian male with no past medical history was
transferred to RPCI. Workup at revealed APL (Table 2) and ATO–
ATRA induction was initiated (Table 1). The following day, the
patient complained of headaches that had been occurring since his
ﬁrst dose of ATRA and were poorly controlled with opiates.
Additionally, the patient was experiencing nausea, which was
relieved with ondansetron. At that point, acetazolamide at a dose
of 250 mg orally twice daily was added to be taken half an hour
prior to ATRA dosing.
After three days, the patient experienced mild relief of head-
aches. Reduction of the ATRA dose by 50% further relieved his pain.
However, he began feeling increasingly nauseous with vomiting
episodes for twenty-four hours. A brain CT showed no abnormal-
ities, and an LP was diagnostic for PTC with an ICP of 39 cm H20.
ATRA was held for three doses and acetazolamide continued. Once
reinitiated, ATRA was titrated up to 30 mg orally twice daily over
ﬁve days with acetazolamide also increased to 500 mg orally twice
daily. Despite acetazolamide, he began to complain of headaches
again and was subsequently changed from acetazolamide to
topiramate 100 mg orally twice daily. ATRA was then titrated over
three days up to full dose (50 mg orally in the morning and 60 mg
Table 1
Schedule of induction and consolidation components of ATO–ATRA dual differentiation regimen [6,32].
Inductiona
ATRAb AND ATOb
45 mg/m2/day divided twice daily in equal doses 0.15 mg/kg/day in 500 mL normal saline intravenous over two hours
Bone marrow biopsy on day 28: If o5% blasts and no abnormal promyelocytes, discontinue ATRA and ATO until occurrence of CRc. Biopsy repeated weekly until criteria
for drug discontinuation met.
Consolidation
ATRAb AND ATOb
45 mg/m2/day divided twice daily in equal doses for two weeks every
4 weeks for a total of 7 cycles
0.15 mg/kg/day in 500 mL normal saline intravenous over two hours 5 days a week for
4 weeks every 8 weeks for a total of 4 cycles
a On days 1–5 of induction therapy, all patients received therapy with methylprednisolone 48 mg PO daily for differentiation syndrome prophylaxis.
b ATRA, All-trans retinoic acid; ATO, arsenic trioxide.
c CR, complete response deﬁned by neutrophil and platelet counts greater than 1109/L and 100109/L, respectively, together with the noted marrow ﬁndings.
Table 2
Disease characteristics of patients developing pseudotumor cerebri (PTC) on dual differentiation therapy.
Case At diagnosis of APL At diagnosis of PTC PTC Symptom Onset
Risk categorya WBCb (cells/L) Pltb (cells/L) PMCb (%) PML-RAR-α FISHb (%þcells) ICPb (cm H20) BMIb kg/m2 ♯ of days after initiation of ATO–ATRA
1 Intermediate 5109 39109 93 90 35 32.1 Induction: day 1
2 Low 0.9109 49109 6 83 39 30.2 Induction: day 1
3 Low 2.5109 77109 66 11 28 37.1 Induction: day 1
4 Low 5.8109 41109 26 92 36 28.5 Induction: day 31
5 Intermediate 3.4109 29109 44 85 27 23.6 Consolidationc: Cycle 1, day 3
Cycle 2, day 3
Cycle 3, day 1
a “Low” risk deﬁned platelet count 440109/L and white blood cell count o10109/L; “Intermediate” risk deﬁned as platelet count o40109/L, and white blood cell
count o10109/L.
b WBC, white blood cell count; Plt, platelet count; PMC, promyelocytes; FISH, ﬂuorescence in-situ hybridization; ICP, intracranial pressure; and BMI, body mass index.
c A “cycle” of consolidation refers to the eight week cycles of arsenic trioxide therapy (total of four cycles).
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orally in the evening) and was continued, with topiramate, for the
remainder of induction. At no point during induction was ATO
interrupted. At the time of reporting, he remains in CR following
the completion of consolidation therapy with maintenance ATRA
50 mg orally twice daily for seven days every other week.
4. Case 3
A 45 year-old Caucasian male with a history of migraines
presented to RPCI for pancytopenia. Workup revealed APL
(Table 2) and the patient was admitted to begin ATO–ATRA
(Table 1). Following his ﬁrst dose of ATRA, the patient developed
severe headaches with 10/10 intensity. CT of the brain was
negative for any abnormality, and he was initiated on hydromor-
phone as needed for two days, with minor relief. At this time, a
diagnostic LP revealed an ICP of 28 cm H20. He was then initiated
on acetazolamide, which was increased to 500 mg orally twice
daily, while continuing full-dose ATRA. He began to also complain
of severe back pain requiring hydromorphone via patient con-
trolled analgesia. With only minor pain relief, the ATRA dose was
reduced by 50% and subsequently held for two additional days.
Despite these measures, the patient continued to have pain,
and his acetazolamide was switched to topiramate, which pro-
duced marked improvement in his head and back aches over a
four-day period at a dose of 100 mg orally twice daily. Due to high
opioid requirements, hydromorphone was converted to metha-
done for chronic management. After reinitiating ATRA at a reduced
dose, it was re-titrated up to full-dose ATRA over ten days and
continued for the remainder of his induction course. Using up to
150 mg twice daily of topiramate, his methadone was tapered
down as back pain improved and headaches disappeared. Upon
discharge, he received a prescription for topiramate to be taken
during ATRA periods of consolidation. With doses of 200 mg orally
twice daily, his methadone was discontinued and switched to
hydromorphone as needed for pain control. He is currently in his
third course of consolidation and remains in CR.
5. Case 4
A 59 year old Caucasian male with a history of chronic renal
insufﬁciency was transferred to our intensive care unit from an
outside hospital, intubated secondary to respiratory failure and
severe mucositis. He arrived on multiple broad spectrum anti-
biotics for treatment of healthcare associated pneumonia and
possible invasive fungal infection. He was found to have APL
(Table 2) and was started on ATO–ATRA induction (Table 1). ATRA
was administered as a compounded suspension down a nasogas-
tric tube during intubation. He continued to be intubated for the
ﬁrst week of the dual differentiation therapy and was extubated
on day ten of his admission. Due to renal failure of unclear etiology
requiring hemodialysis, ATO was dosed every 48 h for the ﬁrst two
weeks of therapy until normalization of renal function. At day 28, a
bone marrow biopsy revealed persistent disease, and a repeat
marrow was planned for one week later.
Thirty one days after initiation of induction, this patient began
to experience 8/10 intensity headaches accompanied by nausea.
Pain was unrelieved by oxycodone. A diagnostic LP revealed an
elevated ICP (Table 1) without CSF abnormalities. ATRA was held
and acetazolamide started at 500 mg orally twice daily. After
holding three doses of ATRA, headaches completely resolved and
ATRA was then restarted at 50% of the original dosage. His ATRA
was able to be titrated up to 67% of the original dose, which he
continued for the remainder of induction. He was discharged with
a prescription for acetazolamide 250 mg orally twice daily to take
during ATRA consolidation. After initiation of consolidation cycle 1,
he was admitted for renal insufﬁciency and metabolic acidosis
secondary to acetazolamide treatment. Since then, he has been
taking sodium bicarbonate tablets 650 mg orally twice daily with
acetazolamide. At the time of this writing, he is currently receiving
cycle 2 of consolidation and remains in CR.
6. Case 5
A 62 year old Caucasian male with a history of thyroid cancer
was transferred to RPCI for further workup of pancytopenia,
fevers, and ﬂu-like symptoms. Work up revealed APL (Table 2).
He successfully completed induction with dual differentiation
therapy without interruption or development of PTC. A bone
marrow biopsy on day 28 met criteria for drug discontinuation,
and the patient was discharged home. Two weeks later, upon
obtaining CR, he began consolidation (Table 1).
Three days into his ﬁrst cycle of consolidation, the patient
presented with complaints of headaches that were unrelieved by
oxycodone. The patient was initiated on acetazolamide 250 mg
orally twice daily to be taken with ATRA, which led to minimal
headache relief. A diagnostic LP revealed PTC (Table 1). As a result,
ATRA was held, acetazolamide discontinued, and topiramate
50 mg orally twice daily initiated. He continued topiramate for
ten days until complete resolution of headaches. At the start of his
next two-week ATRA period, his ATRA was reinitiated at 50% of his
original dose, and topiramate switched back to acetazolamide
250 mg orally twice daily for headache prophylaxis.
Four weeks later, on the ﬁrst day of cycle three, the patient
began to develop headaches again that failed to respond to
oxycodone and acetazolamide 500 mg orally twice daily. Again,
his ATRA was held, acetazolamide discontinued, and topiramate
reinitiated at 50 mg orally twice daily. After complete resolution of
his headaches, ATRA was reinitiated at 50% of his previous dose
and continued, along with topiramate, for the remainder of his
consolidation. Of note, the patient was receiving omeprazole, a
CYP3A4 inhibitor, throughout the duration of his consolidation
therapy. He currently remains in remission four months after
completion of consolidation therapy.
7. Discussion
Dual differentiation therapy has revolutionized the manage-
ment of APL with comparable CR rates to ATRA plus chemotherapy
with decreased risk of many adverse events typically associated
with anthracyclines [6]. Despite the reduction shown in oral,
hematologic, and infectious complications, the combination of
ATO–ATRA is by no means risk free. Treatment with dual differ-
entiation has been associated with signiﬁcantly higher rates of QTc
prolongation and hepatotoxicity compared to ATRA with idarubi-
cin [6]. Although PTC has gone unreported in studies demonstrat-
ing the efﬁcacy of the ATO–ATRA combination [6,32,33], our report
suggests a signiﬁcant incidence of PTC amongst APL patients being
managed with this combination. Of the ten patients identiﬁed as
having received dual differentiation therapy, ﬁve developed PTC,
making our incidence 50%, an alarming rate. It is unclear why our
patient population developed such a high incidence of PTC. We
report the management of our ﬁrst 10 patients receiving dual
differentiation therapy, however it is possible that the incidence
may become diluted once we have treated a larger number of
patients. In addition, our team may have become more vigilant in
screening for PTC and had a lower threshold for doing a LP upon
symptom development given our previous patient's experiences
with PTC from ATO-ATRA. A third possible reason may be related
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to under reporting of this complication of dual differentiation
therapy.
The diagnosis of PTC, based on the Modiﬁed Dandy Criteria, is
made when a patient exhibits an elevated LP opening pressure
above 25 cm H20 with normal CSF composition and radiologic
ﬁndings, and no other explanation for the rise in intracranial
pressure [6]. The most common presenting symptom occurring in
nearly all patients is headache. Other signs and symptoms known
to occur to a lesser degree include nausea, vomiting, transient
visual disturbances, diplopia, papilledema, and pulsatile tinnitus.
Symptoms usually develop within 14 days of ATRA initiation [7].
In our practice, patients receiving ATRA who report persistent
headache that is poorly controlled with opiates or other commonly
used analgesics typically undergo a LP to investigate the possibility
of PTC. The LP is usually considered after more than 24 h of
symptoms, or sooner if the patient reports visual disturbance in
addition to headache. Of the ﬁve cases of PTC presented in this
report, three cases developed symptoms following their very ﬁrst
dose of ATRA. However, in two patients, development of PTC was
delayed (see Table 1), highlighting that PTC can occur at any point
during therapy.
PTC secondary to ATRA administration for APL has been well
described in the literature through case reports in both the
pediatric and young adult populations [7–26] and, among adults,
has been most often associated with obese women of child-
bearing age [34]. However, all patients described in this report
were males with a wide age range and body mass indexes (BMIs)
consistent with an overweight (BMI 25.0–29.9 kg/m2) or obese
(BMIZ30 kg/m2) stature. Given the remarkable incidence of PTC
in our patients receiving ATO-ATRA, it is possible that ATO may
foster the development of this condition in APL patients. PTC has
been reported previously in a 21-year old woman receiving ATO
consolidation therapy for APL without concurrent ATRA [35]. The
mechanism for ATO induced PTC has not been identiﬁed. However,
the primary mechanisms of agents known to cause PTC involves
the alteration of CSF absorption by effects on either the pressure
differential between the central nervous system and venous blood
(increasing inﬂow), or the arachnoid villi (reducing outﬂow) [36].
The suggested mechanism of ATRA induced PTC is a toxic patho-
physiological interaction between vitamin A derivatives and lipid
constituents of the choroid plexus and arachnoid villi, resulting in
inhibited CSF absorption and an increase in intracranial pressure
[37].
Treatment of this condition is necessary to prevent the primary
complication, blindness, secondary to progressive optic disc swel-
ling and atrophy [38]. Management strategies aim to lower intra-
cranial pressure through one or more of the following: removal of
the offending agent (discontinuation of ATRA), removal of CSF
(therapeutic LPs), inhibition of CSF production (acetazolamide),
diuresis (mannitol, glycerin, furosemide), and analgesia. Topiramate
has more recently been described as a treatment option for PTC
[28]. This agent is primarily used in the management of epilepsy,
but is also indicated for migraine prophylaxis [30]. Migraine head-
aches share similar pathophysiological mechanisms with seizures,
including abnormal function of voltage-gated sodium and calcium
channels, reduced GABA mediated inhibition, and increased
glutamate-mediated excitation, many of which may be antagonized
by topiramate [30,39]. It is unclear why topiramate was effective
after the failure of acetazolamide in our patient population. Our
patients received a maximum of 1 g of acetazolamide daily (admi-
nistered as 500 mg twice daily). The optimal dose of acetazolamide
for management of PTC is unknown, however a recent publication
in patients with idiopathic PTC administered an initial total daily
dose of 1 g and titrated up weekly as tolerated to a maximum daily
dose of 4 grams [40]. It is unclear if our patients would have had
better symptom control on higher doses of acetazolamide. We did
not repeat LPs to assess the actual reduction in opening pressure
after initiation of topiramate. Given that ATRA may cause headache
even in the absence of ICP changes, it is possible that topiramate is
simply better at managing such drug induced headache than
acetazolamide is, and that it is not necessarily any better at
decreasing ICP. Such a theory may be supported by the efﬁcacy of
topiramate in managing migraine headache. It is also possible that
the additional mechanisms of action of topiramate, as compared to
acetazolamide, may have played a role in further reducing intra-
cranial pressure lower than that able to be obtained with acetazo-
lamide alone, thus resulting in improved symptom control.
Evidence of the efﬁcacy of topiramate in PTC has been reported
in the literature [41,42]. The largest study, an open-label trial by
Celebisoy and colleagues [41], demonstrated the non-inferiority of
topiramate to acetazolamide in the management of idiopathic
intracranial hypertension in a population consisting primarily of
women of child-bearing age. Patients with secondary causes of PTC,
such as medications, were excluded from this analysis. Although
one of our ﬁve cases was successfully managed with ATRA inter-
ruption and acetazolamide treatment alone, the remaining four
experienced symptom relief only after topiramate was utilized.
Three of four patients receiving topiramate were being closely
monitored in the inpatient setting. Additionally, three patients
were able to safely receive topiramate as outpatients with regularly
scheduled follow-up.
Metabolism of ATRA occurs through the CYP450 system.
Co-administration of agents that inhibit CYP3A4, CYP2C8, and
CYP2C9 has been implicated to increase serum ATRA levels [43].
Theoretically, these interactions could potentiate PTC in patients
managed with differentiation therapy. ATO is primarily metabolized
through methylation. Methyltransferases responsible for this reac-
tion are not members of the CYP450 system, and formal drug
interaction studies with this agent have not been conducted [44].
Standard protocol at our institute dictates that neutropenic patients
receiving dual differentiation therapy are to receive fungal prophy-
laxis with micafungin. Although azole antifungals were not used in
the patients included in our report, two cases were receiving
CYP3A4 inhibitors (diltiazem and omeprazole) during ATO–ATRA
therapy and at onset of PTC symptoms. No other interacting
medications were noted.
In conclusion, our report suggests a high frequency of PTC
(50%) associated with dual differentiation therapy for patients
with low to intermediate risk APL. Our data also represents the
largest case series to date supporting the use of topiramate for the
management of this condition. Clinicians utilizing dual differentia-
tion therapy for the management of low/intermediate risk APL
should be aware of the increased potential for development of this
condition and the appropriate use of agents, including topiramate,
to reduce intracranial pressure, relieve symptoms and, impor-
tantly, permit ATRA re-initiation and dose escalation.
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